

Manuscript version: Author's Accepted Manuscript

The version presented in WRAP is the author's accepted manuscript and may differ from the published version or Version of Record.

Persistent WRAP URL:

<http://wrap.warwick.ac.uk/111381>

How to cite:

Please refer to published version for the most recent bibliographic citation information. If a published version is known of, the repository item page linked to above, will contain details on accessing it.

Copyright and reuse:

The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions.

Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.

Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Publisher's statement:

Please refer to the repository item page, publisher's statement section, for further information.

For more information, please contact the WRAP Team at: wrap@warwick.ac.uk.

Orthostatic hypotension and symptomatic sub-clinical orthostatic hypotension increase risk of cognitive impairment. An integrated evidence review and analysis of a large older adult hypertensive cohort.

Peters R PhD, Anstey K J PhD, Booth A PhD, Beckett N FRCP, Warwick J PhD, Antikainen R PhD, Rockwood K MD , Peters J PhD , Bulpitt C J MD.

Short title: Orthostatic fall and cognitive decline

Ruth Peters (corresponding author)

Neuroscience Research Australia (NeuRA), New South Wales (NSW) 2031 Australia/

School of Psychology University of New South Wales (NSW) 2052, Australia/

School of Public Health, Imperial College London, London. UK.

Email address r.peters@neura.edu.au

Tel: +61416425952 Fax: N/A

Kaarin J. Anstey, NeuRA Sydney New South Wales (NSW) 2031 Australia

School of Psychology, University of New South Wales, Sydney NSW 2052, Australia

Andrew Booth, School of Health and Related Research (SchARR) University of Sheffield, Sheffield, S1 4DA United Kingdom\

Nigel Beckett, Guys and St Thomas' NHS Foundation Trust, London, SE1 7EH United Kingdom

Jane Warwick Warwick Clinical Trials Unit, University of Warwick, Coventry CV4 7A, UK

Riitta Antikainen Center for life course health research/geriatrics, Faculty of medicine,

University of Oulu, Oulu / Medical Research Center Oulu, Oulu University Hospital, Oulu City Hospital. Oulu, Finland.

Kenneth Rockwood, Kathryn Allen Weldon Professor of Alzheimer 's Research, Professor of Geriatric Medicine at Dalhousie University, Halifax, B3H 2E1 Nova Scotia, Canada

Jean Peters, School of Health and Related Research (SchARR) University of Sheffield, Sheffield, S1 4DA United Kingdom

Christopher J Bulpitt, Care of the Elderly, Imperial College London, W12 0NN, UK

Word count 4470 (text), 484 (tables), 2221 (acknowledgements and references).

Abstract

Aims

Systematically reviewing the literature found Orthostatic Hypotension (OH) to be associated with an increased risk of incident dementia but limited data were available in those at highest risk, the hypertensive oldest-old. Our aim was to analyse the relationship between OH and incident cognitive decline or dementia in this group and to synthesize the evidence base overall.

Method and results

Participants aged ≥ 80 years, with hypertension, were from the Hypertension in the Very Elderly Trial (HYVET) cohort. OH was defined as a fall of ≥ 15 mmHg in systolic and or ≥ 7 mmHg in diastolic pressure after two minutes standing from a sitting position.

Subclinical orthostatic fall with symptoms (SOH) was defined as a fall $<$ OH but with unsteadiness, light-headedness or faintness in the week before blood pressure measurement.

Proportional hazard regression was used to examine the relationship between baseline OH, SOH and cognitive outcomes. There were 3121 in the analytical sample, 538 with OH. OH was associated with increased risk of cognitive decline (906 events) Hazard Ratio (HR) 1.36 (95% Confidence Interval 1.14:1.59). For incident dementia (241 events) HR 1.34 (0.98:1.84).

When competing risk of cardiovascular events were taken into account results were HR 1.39 (1.19:1.62) and HR 1.34 (1.05:1.73) respectively. SOH was associated with an increased risk of cognitive decline HR 1.56 (1.12:2.17) and dementia HR 1.79 (1.00:3.20).

Combining the results from the HYVET cohort in a meta-analysis with the existing published literature in this area found a 21% (9%:35%) increased risk of dementia with OH.

Conclusion

OH indicates an increased risk of dementia and cognitive decline. SOH may also be considered a risk factor, at least in older hypertensive adults. Questions remain regarding the mechanisms and whether interventions to reduce impact of OH could protect cognition.

Keywords

| | |
|-------------------------|-------------------|
| Dementia | Cognitive decline |
| Orthostatic hypotension | Hypertension |
| Older adult | |

1. Introduction

Orthostatic hypotension (OH) is a relatively common autonomic failing and is often associated with functional impairment (1). It is commonly defined as a fall in systolic Blood Pressure (BP) of at least 20mmHg and /or a fall of at least 10 mmHg in diastolic BP within 3 minutes of standing,

Older adults are at increased risk of OH due to impaired compensatory mechanisms including decreased baroreceptor (pressure) sensitivity, increased arterial stiffness and reduced parasympathetic tone (2,3). OH is likely to be a risk factor for a variety of negative health consequences, including cardiovascular events, falls, mortality and poor cognition. This is particularly relevant in older adults where hypertension is prevalent and where levels of frailty and comorbidity may also be high (1-3). In 2014 a systematic review found OH to be associated with an increased risk of cardiovascular events (4). The evidence for an association between OH and cognitive decline in the same systematic review was equivocal. The review found only two eligible studies; one reported no relationship between OH and cognitive outcomes (5) and one other reported an increased risk of cognitive decline with OH (6). There remains a lack of high quality evidence, and remaining uncertainty, relating to the association between OH and cognitive decline or dementia.

A link between OH and increased risk of cognitive decline is plausible, either directly via variable cerebral perfusion or via increased cardiovascular risk, clinical or subclinical ischaemic events, or, via failing homeostatic mechanisms associated with both OH and cognitive decline (7). This is also particularly relevant to older adults and those with hypertension in whom cerebral auto-regulatory mechanisms may be less able to adapt (1). With an ageing population and an increased risk of cardiovascular, and cognitive, outcomes associated with increasing age alongside recent work on the role of OH (1-4,7) it is timely to evaluate OH as a predictor for cognitive decline and dementia. To give an updated and unbiased background overview of the current evidence we used systematic methods to review the literature relating to OH as a risk factor for incident cognitive decline and dementia. See supplementary figure 1 and text file 1 for details. Briefly, 21 longitudinal studies on the relationship between orthostatic hypotension and incident cognitive decline or incident dementia were found (5,6,9-27) including populations from Sweden (22 23), Italy(24), the Netherlands (25), Singapore (6) , the United States (26) and France (27). See supplementary tables 1, 2. Study sample mean age ranged from mid (23,26) to late-life (6,24,25,27,33) and follow-up from ~1-28 years (6,23- 27,33).

Three studies reported presence of OH was associated with an increased risk of dementia (22,

25, 27). One study found no relationship between baseline OH and dementia (23), one found no relationship between OH and cognitive decline (26). Two found no association between OH and risk of a fall in cognitive screening score (6,24). Study quality was adequate although details were often lacking, see supplemental table 3.

Overall, evidence suggests that a diagnosis of OH may be associated with a subsequent increased risk of dementia. However, there are no data available on those at highest risk of hypertension, OH and cognitive decline or dementia (the oldest old). Furthermore, few studies have investigated the relationship between the magnitude of the orthostatic fall and the degree of risk (i.e. the potential dose response), or the possible influence of ‘sub-clinical’ orthostatic fall. A greater understanding of relationship between orthostatic fall and cognitive outcome in older adults is essential to be able to identify those at risk of cognitive decline or dementia and to provide appropriate clinical support.

Our aim was to examine the relationship between orthostatic fall and subsequent cognitive decline or dementia in an older adult hypertensive population using data collected as part of the Hypertension in the Very Elderly Trial and to combine our results with the existing evidence base using meta-analysis.

2. Methods

HYVET was a double blind placebo controlled trial of an antihypertensive regimen (thiazide-like diuretic, indapamide 1.5 sustained release, with the optional addition of an angiotensin converting enzyme inhibitor, perindopril 2-4mg) in those aged 80 and over. Participants with hypertension were recruited from over 90 primary and secondary care centres in 13 countries and randomised to receive trial treatment or matching placebo. All required ethical approvals were obtained. Participants were seen during a two-month placebo run-in phase, at baseline, every three months during the first year and every six months thereafter. Cognitive function was assessed at baseline and annually thereafter using the Mini-Mental State Exam (MMSE). A reduction in MMSE score to below 24 or by more than three points in twelve months was classified as cognitive decline and triggered a dementia assessment. Dementia was diagnosed in accordance with the Diagnostic Statistical Manual IV (DSMIV). Dementia was classified as present or absent. An independent expert dementia committee blind to trial treatment allocation had access to all data and reviewed and validated all dementia endpoints. Other trial endpoints were reported as they occurred and included death, stroke, myocardial infarction and incident or worsening heart failure. Validation of trial endpoints was carried out by a trial endpoint committee of international experts blinded to trial treatment allocation and with full access to supporting documentation, for example, death certificates, hospitalisation reports etc:

To collect data on self-reported symptom burden HYVET trial participants were also asked to self-complete a symptom questionnaire at baseline and annually thereafter. This questionnaire was based on the Bulpitt and Fletcher questionnaire and included a list of symptoms relevant to hypertension and its treatment (28). Participants were asked to rate the level to which they had been affected by a symptom over the last week. The symptoms light-headedness, unsteadiness and faintness were selected as relevant to orthostatic drop.

The full details of the HYVET protocol have been published elsewhere (29,30). In brief, to enter the HYVET trial participants were required to be aged 80 or over at randomisation, to have no clinical diagnosis of dementia, a mean systolic BP 160 to 199mm Hg and a standing systolic BP \geq 140mm Hg. The sitting BP was taken twice after sitting for five minutes and the standing BP taken twice after standing for two minutes. At study baseline BP was measured using a mercury sphygmomanometer. As supine BP was unavailable OH was calculated based on a fall of \geq 15mmHg systolic BP and or a fall of \geq 7mmHg diastolic BP from

sitting to standing (31, 32). A novel category of subclinical orthostatic fall with recent symptoms (SOH) was also created. SOH was defined as any fall in systolic BP of $<15\text{mmHg}$ on standing and any fall in diastolic BP of $<7\text{mmHg}$ on standing plus symptoms of lightheadedness and or unsteadiness and or faintness reported by the participant as having bothered them ‘a lot’ or ‘extremely’ during the preceding week. The SOH category was adapted from the orthostatic intolerance definition used by Elmståhl et al (22) and intended to examine a potential subclinical population (3).

2.1. Statistical Methods

The analytical data set consisted of HYVET trial participants who had at least one repeated assessment of cognitive function (allowing evaluation of cognitive decline), complete baseline BP measurements and, in accordance with the literature (6,22,25) were without prior stroke. OH was classified as present or absent at baseline.

The difference in baseline characteristics between those who were included in the analytical sample and those who were excluded, and between those with and without OH, was assessed using Chi squared and Wilcoxon tests, as appropriate. Proportional hazard (Cox) regression was used to assess the relationship between those classified as having OH and subsequent cognitive decline or incident dementia. Time to event was calculated from trial entry (the date of first cognitive and blood pressure measure) to the earliest date of event, date of death or date of last follow up. The date of the study visit where cognitive decline was identified was taken as the date of event for cognitive decline. The date that cognitive decline was identified was also used for date of dementia where further testing confirmed dementia diagnosis. This is a pragmatic choice since the time interval between the visit where cognitive decline was identified and the subsequent examination to verify diagnosis of dementia varied and as the onset of dementia is an insidious process. Models were stratified (by age (80-84, ≥ 85), sex and education) and adjusted for key cardiovascular and cognitive risk factors (baseline sitting systolic and diastolic BP, trial treatment (antihypertensive or placebo) and presence of diabetes). Proportional hazard assumptions were checked using Grambsch and Therneau tests (33). Overall model fit was assessed visually by plotting the Nelson-Aalen cumulative hazard function against the Cox-Snell residuals. Analyses carried out using SAS 9.3, Stata and Statsdirect 3.

The incidence of mortality, cardiovascular events (myocardial infarction, stroke or heart failure), cognitive decline and/or dementia may be interrelated or may all be considered manifestations of the same cardiovascular disease process. We therefore performed two

further Cox regression analyses, each using a composite endpoint combining cognitive and cardiovascular events in a time to first event model to give greater statistical power and a more holistic outcome measure. In the first, incident dementia or fatal and non-fatal cardiovascular events (heart failure, myocardial infarction, stroke) were defined as an event and in the second, incident cognitive decline and fatal and non-fatal cardiovascular events (heart failure, myocardial infarction, stroke) were defined as an event.

Additional analyses were performed with adjustment for incident OH occurring during study follow-up; and, because blood pressure variability may increase the risk of both OH and cognitive decline, analyses were rerun with additional adjustment for visit to visit variability calculated as the standard deviation of the sitting systolic BP values.

Further analyses in the subset of participants who also had symptom data (i.e. had completed the symptom questionnaire) allowed comparison of those with OH, SOH and neither. The baseline characteristics of these three groups were compared using chi squared and analysis of variance tests for categorical and continuous variables, as appropriate. Pairwise differences were investigated post-hoc using the Tukey-Kramer (equal variances) or W test (unequal variances) for continuous variables and by inspection of the adjusted chi-squared residuals for categorical variables.

Proportional hazards (Cox) regression was used to assess the relationship between orthostatic status and subsequent cognitive decline or incident dementia with orthostatic status categorised as a 3-level variable (OH, SOH or neither (reference group)). There were no missing data for the exposure, outcome or confounding variables used in the analyses.

2.2. Sensitivity analyses

The Cox regression analysis was repeated: (i) in those with baseline MMSE >26 (those scoring above 26 at baseline are considered unlikely to have pre-existing cognitive decline, the selection of this population therefore allowed us to rerun the analyses with less risk of including undiagnosed dementia cases.); (ii) for systolic and diastolic OH separately; (iii) for continuous BP fall and risk of subsequent cognitive decline or incident dementia; (iv) using the traditional and more severe classification of OH (a fall of >20mmHg systolic and or >10mmHg diastolic);

Finally the association between baseline OH and subsequent attrition (mortality or drop out) was examined in the analytical sample and inverse probability weighting used to evaluate

potential bias stemming from including only those with data on cognitive decline and without stroke.

2.3. Meta-analysis

Where possible the results from the HYVET analyses were combined with the existing evidence base was combined with using meta-analytical techniques.

3. Results

3.1. Study population

There were 3845 participants randomised into the HYVET trial with a mean follow up of 2.0 years. Of those, 508 were excluded from the analysis because they had no cognitive follow-up assessment and a further 216 due to prior stroke. The analytical sample therefore included 3121 with data on OH and outcome. The subset of those with symptom data and in whom SOH could be calculated contained 2109 participants. (See supplementary Figure 2 for details).

3.2. Orthostatic hypotension (OH)

3.2.1. Characteristics of the sample (OH)

There were 538 participants with OH and 2583 without. Those with OH had higher sitting systolic BP ($P<0.0001$) and lower standing systolic ($P<0.0001$) and diastolic pressure ($P<0.0001$) as would be expected. They were also older ($P=0.004$), They also had a lower mean MMSE score at baseline ($P=0.0003$), shorter follow-up ($P<0.0001$) and a higher percentage of this group were classified as having incident cognitive decline ($P<0.0001$) (see Table 1 for details).

Table 1 here

3.2.2. Proportional hazard regression (OH)

The estimates of the hazard ratios from the Cox regression models for the association between baseline OH and risk of cognitive decline (Hazard Ratio (HR) 1.36 (1.15:1.59)), and between baseline OH and development of dementia (HR1.34 (0.98:1.84)), were similar. (Table 2). There was little change in the estimates of hazard ratios when composite endpoints combining cognitive and cardiovascular outcomes were used, HR1.39 (1.19:1.62) for cognitive decline and cardiovascular events, and HR1.34 (1.05:1.72) for dementia and cardiovascular events. There was no relationship between OH and mortality or cardiovascular events alone. Further adjustment for blood pressure variability did not change the direction, magnitude or significance of the results.

There were 315 incident OH cases occurring during study follow-up $n=169$ (5.6/100 patient years of follow-up) in the placebo and $n=146$ (4.5/100 patient years) in the actively treated group. Additional adjustment for incident OH resulted in the relationship between OH and incident dementia reaching statistical significance.

Further sensitivity analyses rerunning fully adjusted models in those with baseline MMSE scores >26 (n=1648) resulted in a similar pattern of results and statistical significance as seen when analysing the whole cohort. The only difference was a loss of statistical significance for one analysis, the relationship between OH alone and cognitive decline.

Table 2 here

3.3. Subclinical orthostatic fall with recent symptoms (SOH) and orthostatic hypotension (OH)

3.3.1. Characteristics of the sample (SOH, OH)

In the subset of those for whom symptom data were available (n=2109) 105 reported SOH, 381 OH and 1623 neither. The baseline characteristics of the three groups are summarised in Supplementary Table 4.

When examining the participants with both cognitive and symptom data there were 105 with subclinical orthostatic fall and positive symptoms, seven with symptoms but neither subclinical nor clinical orthostatic fall and four with symptoms and clinical fall. There are significant differences in the majority of measures between these groups at baseline (all except sitting systolic BP) but there is no consistent suggestion of a linear trend and the only clinically significant differences were between those without any orthostatic fall and those with OH.

3.3.2. Proportional hazard regression (SOH, OH)

The estimates of HRs from the Cox regression models are shown with the associated 95% confidence intervals in Table 3 and Figure 1. Both SOH and OH were associated with an increased risk of cognitive decline. For SOH, HR1.56 (95%CI 1.12:2.17) and for OH HR1.40 (95%CI 1.15:1.69). For cognitive decline and cardiovascular events the results were SOH, HR1.51 (95% CI 1.11:2.06) and OH, HR1.43 (95% CI 1.20:1.72), respectively). SOH was also associated with an increased risk of dementia HR1.79 (95% CI 1.00:3.20) and dementia and cardiovascular events HR1.79 (95%CI 1.15:2.78).

Further adjustment for blood pressure variability did not change the direction, magnitude or significance of the results. Additional adjustment for incident OH resulted in the relationship between OH and the composite endpoint, incident dementia with cardiovascular, events reaching statistical significance.

Further sensitivity analyses rerunning fully adjusted models in those with baseline MMSE scores >26 and symptom data (n=914) resulted in a similar pattern of results but the association between OH and cognitive decline was no longer significant.

Additional analyses examining cardiovascular events and mortality alone found SOH to be associated with an increased risk of cardiovascular events HR2.28 (95% CI 1.25:4.14) and mortality HR2.97 (95% CI 1.76:5.01).

Figure 1 here. Table 3 here

Further examination of the role of symptoms (from the symptoms questionnaire) revealed that presence of self-reported light-headedness and or unsteadiness and or faintness alone (regardless of orthostatic fall) and experienced over the preceding week were not associated with incident cognitive decline or dementia. Rerunning the analysis without the inclusion of symptom data (i.e. SOH classified based on subclinical orthostatic fall alone) resulted in non-significant relationships between sub-clinical orthostatic fall and cognitive decline HR1.01 (0.82:1.24) and dementia HR 1.05(0.70:1.58).

Model fit was adequate in all cases and the proportional hazards assumption was not violated.

3.4. Sensitivity analyses

3.4.1. Systolic hypotension and diastolic hypotension.

The analyses were repeated with OH defined using systolic blood pressure fall, systolic OH (n=218) or diastolic blood pressure fall, diastolic OH (n=400) (Supplementary table 5).

Diastolic OH was associated with an increased relative risk of; cognitive decline HR1.47 (1.23:1.75), dementia HR1.69 (1.22:2.34), cognitive decline and cardiovascular events HR1.49 (1.26:1.75) and dementia and cardiovascular events HR1.54 (1.18:2.00). There were no significant associations for systolic OH.

Repeating the analyses selecting only those with systolic OH but without diastolic OH (n=138) and diastolic OH without systolic OH (n=320) did not materially change the results.

3.4.2. Orthostatic fall

We investigated the relationship between magnitude of the orthostatic fall at baseline and risk of cognitive decline by repeating the Cox regression analysis with orthostatic fall as a continuous variable and for systolic and diastolic BP separately. On average there was a 26% increased relative risk of cognitive decline per 10mmHg increase (i.e. greater fall in BP) in orthostatic drop in diastolic BP HR1.26 (1.09:1.42). For systolic BP the results were HR1.04 (0.94:1.15) per 10mmHg increase.

3.4.3. Traditional and more severe classification of OH (a fall of >20mmHg systolic and or >10mmHg diastolic);

The Cox regression analysis was repeated using the classic, more conservative, definition of OH (see methods section) and the results presented in Supplementary Table 6. Orthostatic hypotension was associated with an estimated 49% increased relative risk of developing cognitive decline HR=1.49 (95%CI 1.16 to 1.90). This did not change markedly when cognitive decline and cardiovascular events were combined.

3.4.4. Attrition and inverse probability weighting:

There was no association between OH and subsequent drop out or death (events=650) OR0.86 (95% CI 0.67 to 1.10). Inverse probability weighting weighted by age, sex and baseline MMSE score found similarly positive associations between OH and incident cognitive decline (β 0.078 (95%CI 0.045:0.130)) $P<0.0001$ and dementia (β 0.027 (0.003:0.052)) $P=0.034$. This implies that the exclusion of those with prior stroke and without follow-up cognitive assessment did not bias the sample in such way as to materially affect the results.

3.5. Meta-analysis combining the results from the systematic review and HYVET study. Summary data showing the relationship between presence or absence of OH and incident dementia was reported in the published literature for the Rotterdam Study (HR1.15 (95%CI 1.00:1.34)), the 3 City Study (HR 1.19 (95%CI0.98:1.46)), the Malmö study (HR 1.18 (0.73:1.89)), the Swedish Good Aging in Skåne Study (OR 1.93 (95%CI1.19:3.14)), and the HYVET study (HR 1.34 (95%CI 0.98:1.84)) (22,23,25,27).

The meta-analysis suggested that increased relative risk of dementia was associated with presence of OH. The pooled ratio was 1.21 (1.09:1.35) for fixed effects analysis. See supplementary analyses 1 for details of the meta-analysis and forest plot showing the five included studies. The I^2 value for the meta-analysis was 10.4% and there was no significant risk of publication bias (Egger bias $p=0.1463$). There were insufficient data available from the previously published studies to allow separate meta-analysis relating to systolic, diastolic or subclinical OH.

See supplementary tables 1-2 for details of the studies included in the meta-analysis (populations, age, sex, follow-up, assessment of OH, assessment of cognitive function, analysis methods and results for these studies). Supplementary table 3 further details the assessment of study quality and risk of bias.

4. Discussion

These analyses present new data and shed new light on the relationship between OH and cognitive impairment and dementia.

4.1. Orthostatic hypotension and HYVET

When the relationship between OH and incident cognitive decline and dementia was assessed in an older adult hypertensive population from the HYVET trial, baseline OH (sitting to standing) was associated with a 36% increased risk of cognitive decline HR1.36 (1.15:1.59) and a similar point estimate but non-significant relationship with incident dementia HR1.34 (0.98:1.84). Using composite endpoints (i.e. including cardiovascular events) resulted in significant associations with both cognitive decline and dementia, and did not change the magnitude of the point estimates. Further examination of the relationship between subclinical orthostatic drop and cognitive outcomes revealed SOH to be associated with a 56% increased risk of cognitive decline HR1.56(1.12:2.17)) and a 79% increased risk of incident dementia HR1.79 (1.00:3.20)). Results were similar for composite cognitive-cardiovascular endpoints. When systolic and diastolic OH were examined separately results were significant only for diastolic drop.

The relationships between OH and cognitive outcomes in the HYVET trial are not entirely congruent with the literature. In the HYVET data the relationship between OH and cognitive decline was stronger than the equivalent relationship with dementia although both were of similar magnitude, however, there were fewer dementia cases than cases of cognitive decline and thus less power to detect a relationship. The strength of the relationship with SOH and cognitive decline was also greater than the relationship between SOH and incident dementia, however both were statistically significant despite the restricted numbers available for these analyses. Neither presence of symptoms alone, nor subclinical orthostatic fall without symptoms were associated with an increased risk of cognitive decline or dementia therefore the presence of symptoms alongside orthostatic drop may be of particular importance in identifying those at risk of cognitive decline or dementia. Unfortunately there were too few cases of OH and presence of symptoms to allow evaluation of this category.

The stronger relationship between diastolic as compared to systolic OH and cognitive outcomes in the HYVET trial must be interpreted with caution. Although it is similar to that reported for the Swedish Malmo study and may represent a particular risk associated with a

more pulsatile flow and decrease of perfusion in diastole, another explanation relevant to the HYVET data is that the trial inclusion criteria are based on systolic rather than diastolic pressures meaning that the systolic pressures were more homogeneous and clustered just above the required cut-point for trial entry. To enter the HYVET trial participants were required to have a mean systolic BP 160 to 199mmHg and a standing systolic BP ≥ 140 mmHg. This resulted in a study population without severe OH and, since there were fewer entrants with very high systolic BP, a mean baseline systolic BP close to the entry threshold. Diastolic pressures did not suffer from the same limitation.

Further limitations include the potential for unmeasured confounding and use of a clinical trial population with randomly allocated antihypertensive treatment and placebo arms.

Although we found no relationship between trial treatment group and cognitive outcomes (34) and the analyses were adjusted for trial treatment group it remains possible that there may have been an undetected impact of trial treatment on the relationship between orthostatic drop and cognitive outcomes. The relatively short follow up and the potential for interaction between blood pressure and cognitive function over a decades long prodromal period prior to the identification of decline is an additional limitation. We have a lack of understanding relating to the long term relationship between blood pressure and cognition over the life-course and a lack of data prior to participant entry into the HYVET trial at ~80 years of age which inevitably restricts our ability to evaluate causality. There is also a challenge in disentangling the potential relationship between early cognitive decline, impaired medication adherence and subsequent change in BP control and OH. Despite this, the results from the HYVET population are in line with those of longer population studies (22,23,25,27). It may be that OH had been present and incrementally increasing risk either directly or indirectly for many years prior to study start, however, we have no data on OH prior to entry into the HYVET trial. Alternatively the association of OH and cognitive outcomes in this very elderly population may represent failing homeostatic mechanisms and increased blood pressure variability associated with both OH and cognitive decline. Additional adjustment for visit to visit variability had no impact on the results, however, a lack of sufficient data relating to 24 hour blood pressure variability (112 HYVET participants had ambulatory blood pressure measurement at baseline) prevented further examination of this area. In fact, since studies with both long and short term follow up demonstrate a relationship between OH and increased risk, the exact causal pathways, whilst still needing to be established (35), do not change the overall categorization of OH as an easily measurable factor signalling increased risk.

4.2. Orthostatic hypotension and meta-analysis combining the published literature and the HYVET results

The meta-analysis combining HYVET with the published literature found OH to be associated with a 21% increased risk of dementia. Inevitable limitations include variation in length of follow-up, confounders, population characteristics and in the definition and assessment of OH and cognitive outcome plus risk of bias present in the constituent studies. This means that generalisability is limited and, as is common in meta-analyses, caution must be applied.

4.3. Summary

The literature overall, including HYVET, is remarkably similar in showing a relationship between OH and risk of dementia. In addition a possible dose response may mean that even subclinical orthostatic fall is associated with raised risk especially in the presence of symptoms associated with OH. However, our analyses cannot establish causality and further research is needed to more fully understand the nature of the relationship between orthostatic drop, speed of recovery, potential difference between systolic and diastolic drop, role of symptoms, related measures such as blood pressure variability, arterial stiffness, impact of early cognitive change on medication availability or adherence and causal pathways (35, 36). Causality in this area is complex and although we know from the Discontinuation of Antihypertensive Treatment in Elderly People on Cognitive Functioning trial that stopping antihypertensives, at least in those with mild cognitive deficit, increased probability of recovery from OH, this association was not present in the intention to treat analysis, and had no impact on cognitive measures (37). Furthermore there was no relationship between antihypertensive use and OH in HYVET and antihypertensive use reduced risk of cardiovascular events and mortality (30) meaning we cannot simply recommend the cessation or reduction of antihypertensives. A key question therefore is whether other interventions to minimise the impact of OH (35-38) have any impact of cognitive outcomes.

Conclusion

Orthostatic hypotension appears to be associated with an increased risk of dementia and of cognitive decline and may be a clinically useful indicator of increased risk. Attention should also be paid to those with subclinical orthostatic drops alongside symptoms indicative of variable cerebral perfusion.

Sources of funding

This work was not supported by a particular funding body.

RP is funded by the Australian Dementia Collaborative Research Centre

KJA is funded by NHMRC Fellowship APP1102694.

AB's literature search and methodological input was undertaken under his University of Sheffield employment contract. He has no financial conflicts of interest

KR is funded through the Dalhousie Medical Research Foundation as the Kathryn Allen Weldon Professor of Alzheimer's Research and receives research funding from the Canadian Institutes of Health Research, the Canadian Frailty Network and the Fountain Family Research Fund of the Queen Elizabeth II Health Sciences Centre

The HYVET trial was funded by academic grants from the British Heart Foundation and Servier International to Imperial College London.

Funding bodies had no role in the inception, design, completion or publication of this work

Acknowledgements:

RP had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis

RP designed the systematic review and analyses of the orthostatic hypotension exposure, was one of the systematic reviewers, carried out the analyses and drafted the manuscript.

KA aided in the design of the systematic review and commented on the manuscript

AB aided in the design of the systematic review and commented on the manuscript

NB aided in the design of the OH analyses and commented on the manuscript

JW aided in the design of the OH analyses, carried out the analyses and commented on the manuscript

RA aided in the design of the OH analyses and commented on the manuscript

KR aided in the design of the OH analyses and commented on the manuscript

JP aided in the design of the systematic review, was one of the reviewers and commented on the manuscript

CB was the CI for the HYVET trial and commented on the manuscript.

All persons mentioned in the acknowledgements have given written consent.

The HYVET trial is registered with ClinicalTrials.gov number NCT00122811

HYVET coordinating team at Imperial College London (1999 to 2008);

HYVET Committees: Steering Committee: T. McCormack, J. Potter, B.G. Extremera, P. Sever, F. Forette, D. Dumitrascu, C. Swift, J. Tuomilehto, J. Coope (retired in 2001), C. Nachev (deceased); Data Monitoring Committee: J. Staessen, L. Thijs, R. Clarke, K. Narkiewicz; End Points Committee: C. Davidson (retired in 2003), J. Duggan, G. Leonetti, N. Gainsborough, M.C. De Vernejoul, J. Wang, V. Stoyanovsky; Dementia Validation Committee: J. Tuomilehto, R. Clarke, A. Waldman, I. Walton, C. Ritchie; Ethics Committee: R. Fagard, J. Grimley Evans, B. Williams;

Investigators: (*National Co-ordinators)

Australia — R. Warne* and I. Puddey*, M. Woodward, R. Penhall, C. Inderjeeth, S. Roger, R. Scholes, C. Johnson; Belgium — H. Celis*, G. Adriaens, W. Onsea, K. Cornelli, D. Vantroyen, P. Cleen, P. de Voogt; Bulgaria — C. Nachev* (deceased) (national coordinator from 1998 to 2005), V. Stoyanovsky* (national coordinator after 2005), P. Solakov, R. Prokopova, E. Mantova, D. Smilkova, S. Mantov, K. Yankulova, R. Kermova, D. Popov, V. Sirakova, V. Gergova, D. Kamenova, F. Grigorov, T. Vassileva, R. Alahverdian, M. Tzekova; A. Postadjian, M. Geneva, V. Mincheva, T. Petrusheva, A. Toncheva, I. Gruev, V. Tsanova; China — L. Liu*, H. Ge, S. Wang, J. Wang, W. Zhang, S. Jin, L. Ge, Y.F. Lu, S. Ma, L. Shen, J. Guo, Z. Lv (deceased), R. Huang, X. Li, B. Guo, GE Yuan, T. Zhang, L. Zhang, J. Feng, Z. He, J. Wang, L. Deng, L. Liu, Q. Yuan, F. Zhang, H. Li, D. Wang, K. Yang, M. Sun, H. Liu, X. Yan, F. Ren, J. Tang, M. Zhao, X. Luo, H. Zhou, H. Sang, Jie Wang, L. Yan, Zhixing Wang, J. Zhang, Chengzhi Wang,; Finland — R. Antikainen*, T. Strandberg, T. Konttila, A. Hynninen, M. Jääskivi, J. Airas, T. Jääskeläinen, J. Tuomilehto, H. Litmanen, T. Karhi, H. Yliaharsila; France — F. Forette*, J. Doucet, J. Belmin, A. Benetos, G. Berrut, T. Boge, M. Bonnefoy, A. Carre, N. Charasz, J. Covillard, T. Dantoine, M. Escande, Y. Frances, R. Joire, C. Jeandel, S. Legrain, A. Lion, M. Maillet-Vioud, J.P. Escaillas, S. Meaume, P. Pfitzenmeyer, F. Puisieux, Quercy, O. Rodat, J. Soubeyrand, B. de Wazieres, H. Hindennach, L. Lugassy, J. Rossi, M. Martel, J.-M. Paladel, C. Ravier, A. Visconti, J.P. Gallet, D. Zygouritsas, D. Charles, F. Flamand, G. Grandmottet, M. Grandmottetegermann, C. Gevrey, P.L. Mesnier, G. Robert, C. Besset-Prat, A. Brousse, P. Lafont, J. Morelli, P. Vernede, A. Volkmann, X. Bodin, B. Destrupe, R. Eoche, A. Boye, F. Seropian, P. Gernigon, D. Meker, J. Thomere, Y. Thual, F. Volny, E. Grassart, M. Herent, D. Lejay, J.-P. Lopez, B. Mannessier, G. Pruvost, J.-C. Urbina; Ireland — J. Duggan*; New Zealand — C. Anderson*, S. Lillis, J. Gommans, H. Senior; Poland — T. Grodzicki*, Z. Chodorowski, Z. Gaciong; Romania — D. Dumitrascu*, M. Comsa, V. Sandru, G. Prada, M. Dunca-Moisin, D. Jianu, D. Jinga-Lazar, V. Enachescu, C. Zaharia; Russia — Y. Nikitin*, A. Kirichenko, L. Olbinskaya, A. Martynov, V. Zadionchenko, V. Moiseev, G. Storozhakov, S. Nedogoda, R.S. Karpov, O. Barbarash, G.

Efremushkin, V. Kostenko, M. Boyarkin, S. Churina, T. Tyurina, M. Ballyuzek, L.Ermoshkina, A. Timofeev, S. Yakusheva, N. Shilkina, V. Barbarich, L.Latunceva, S. Burakova, T. Ripp, S.Pekarsky, V.Mordovin; Tunisia — A. Belhani*, E. Boughzela, S.Soraya, B. Youssef-Zouari, A.B. Khalfallah, M.H. Houman, A.K. Abida; United Kingdom — C. Rajkumar*, M.Wilkins, N.D. Pandita-Gunawardena, J. Potter, E. Ekpo, M. Price, N. de Kare-Silver, A. Starczewski, S. Chandran, N. Nasar, M. Datta-Chaudhuri, T. McCormack, N. Majmudar, A. Gordon, L. Brawn, T Solanki, F.Dockery, R.Schiff.

We wish to acknowledge the work of Professor C. Nachev (Steering committee member, National Coordinator of Bulgaria and HYVET investigator from 1998 until his death in 2005)

Conflict of interest

KR founded DGI Clinical Inc., which has contracts with pharma for individualised outcome measurement and for data analytics, including in dementia studies with Otsuka and Roche. In 2017 he participated in an Advisory Board meeting on dementia for Lundbeck and in 2014 spoke at a satellite symposium at the Alzheimer Association International Conference, sponsored by Nutricia.

No other conflicts of interest are reported.

References

1. Ricci F, De Caterina R, Fedorowski A Orthostatic Hypotension: Epidemiology, Prognosis, and Treatment. *J Am Coll Cardiol.* 2015;**66**:848-60. doi: 10.1016/j.jacc.2015.06.1084.
2. Shibao C, Lipsitz L, Biaggioni I behalf of the American Society of Hypertension Writing Group. Evaluation and treatment of orthostatic hypotension *J Am Soc Hypertens* 2013; **7**:317-324
3. Perlmutter L, Sarda G, Casavant V, O'Hara K, Hindes M, Knott P, Mosnaim A. A review of orthostatic BP regulation and its association with mood and cognition. *Clin Auton Res* 2012; **22**: 99-107
4. Angelousi A, Girerd N, Benetos A, Frimat L, Gautier S, Weryha G, Boivin JM. Association between orthostatic hypotension and cardiovascular risk, cerebrovascular risk, cognitive decline and falls as well as overall mortality: a systematic review and meta-analysis. *J Hypertens* 2014; **32**: 1562-1571
5. Viramo P, Luukinen H, Koski K, Laippala P, Sulkava R, Kivela S. Orthostatic hypotension and cognitive decline in older people. *JAGS* 1999; **47**: 600-604
6. Yap P, Niti M, Yap K, Ng T. Orthostatic hypotension, hypotension and cognitive status: early comorbid markers of primary dementia. *Dementia and Geriatric Cognitive Disorders* 2008; **26**: 239-246
7. O'Callaghan S, Kenny RA. Neurocardiovascular instability and cognition. *Yale J Biol Med.* 2016; **89**: 59-71
8. Critical Appraisal Skills Programme <http://www.casp-uk.net/casp-tools-checklists> accessed 07 April 2017
9. Perlmutter L, Greenberg J. Do you mind standing? Cognitive changes in orthostasis. *Exp Aging Res.* 1996;**4**:325–341.
10. Rutan G, Hermanson B, Bild D, Kittner S, LaBaw F, Tell G. on behalf of the CHS Collaborative Research Group Orthostatic Hypotension in Older Adults The Cardiovascular Health Study *Hypertens* 1992;**19**:508-519
11. Kuo H, Sorond F, Iloputaife I, Gagnon M, Milberg W, Lipsitz L. Effect of BP on Cognitive Functions in Elderly Persons. *J Gerontol A Biol Sci Med Sci.* 2004; **59**: 1191–1194
12. Bendinin C, Angelini A, Salsi M, Finelli ME, Martini E, Neviani F, Mussi C, Neri M. Relation of neurocardiovascular instability to cognitive emotional and functional domains. *Archives of Gerontology and Geriatrics* 2007; Supplement **1**: 69-74
13. Press Y, Punchik B, Freud T Orthostatic hypotension and drug therapy in patients at an outpatient comprehensive geriatric assessment unit. *J Hypertens* 2016; **34**:351–358

14. Punchik B, Freud T, Press Y. The association between orthostatic hypotension and cognitive state among adults 65 years and older who underwent a comprehensive geriatric assessment. *Medicine* 2016; **95**:29(e4264)
15. Scuteiri A, Tesaro M, Guglini L, Lauro D, Fini M, Daniele N. Aortic stiffness and hypotension episodes are associated with impaired cognitive function in older subjects with subjective complaints of memory loss *International Journal of Cardiology* 2013; **169** :371–377
16. Verghase J, Lipton R, Hall C, Kuslansky G, Katz M. Low BP and the risk of dementia in very old individuals *Neurol* 2003;**61**:1667–1672
17. Waldstein S, Giggey P, Thayer J, Zonderman A. Nonlinear Relations of BP to Cognitive Function, The Baltimore Longitudinal Study of Aging *Hypertens* 2005;**45**:374-379
18. Wu C, Zhou D, Wen C, Zhang L, Como P, Qiao Y. Relationship between BP and Alzheimer's disease in Linxian County, *China Life Sciences* 2013;**72**: 1125–1133
19. Feeney J, O'Leary N, Kenny R. Impaired orthostatic BP recovery and cognitive performance at two-year follow up in older adults: The Irish Longitudinal Study on Ageing *Clin Auton Res* 2016; **26**:127–133
20. Ganguli M, Lee C, Snitz B, Hughes T, McDade E, Chang C. Rates and risk factors for progression to incident dementia vary by age in a population cohort *Neurol* 2015;**84**:72–80
21. Hayakawa T, McGarrigle C, Coen R, Soraghan C, Foran T, Lawlor B, Kenny R. Orthostatic BP behaviour in people with mild cognitive impairment predicts conversion to dementia. *JAGS* 2005; **63**: 1868-1873
22. Elmståhl S, Widerström E. Orthostatic intolerance predicts mild cognitive impairment: incidence of mild cognitive impairment and dementia from the Swedish general population cohort Good Aging in Skåne. *Clin interventions in Aging* 2014; 9: 1993-2002
23. Holm H, Nägga K, Nilsson E, Melander O, Minthon L, Bachus E, Fedorowski A, Magnusson M. Longitudinal and postural changes of BP predict dementia: the Malmö Preventive Project. *Eur J Epidemiol* 2017; 32:327-336
24. Curreri C, Giantin V, Veronese N, Trevisan C, Sartori L, Musacchio E, Zambon S, Maggi S, Perissinotto E, Corti MC, Crepaldi G, Manzato E, Sergi G. Orthostatic Changes in BP and Cognitive Status in the Elderly: The Progetto Veneto Anziani Study. *Hypertens*. 2016; **68**: 427-435.
25. Wolters F, Mattace-Raso F, Koudstaal P, Hofman A, Ikram M, Heart brain connection collaborative research group. Orthostatic hypotension and the long-term risk of dementia: a population based study. *PLoS Med* 2016; DOI:10.1371/journal.pmed.1002143
26. Rose J, Couper D, Eigenbrodt M, Mosley T, Sharrett R, Gottesman R. Orthostatic Hypotension and Cognitive Function: The Atherosclerosis Risk in Communities Study *Neuroepidemiol* 2010;**34**:1–7

27. Cremer A, Soumaré A, Berr C Dartigues JF, Gabelle A, Gosse P, Tzourio C. Orthostatic hypotension and risk of incident dementia, results from a 12 year follow-up of the Three-City study cohort. *Hypertens* 2017; **70**:00-00 DOI:10.1161/HYPERTENSIONAHA.117.09048
28. Bulpitt C J and Fletcher A E. The measurement of quality of life in hypertensive patients: a practical approach. *Br J Clin Pharmacol* 1990;**30**:353-364
29. Bulpitt CJ, Fletcher AE, Beckett N Coope J, Gil-Extremera B, Forette F, Nachev C, Potter J, Sever P, Staessen J, Swift C, Tuomilehto J. Hypertension in the Very Elderly Trial (HYVET) Protocol for main trial. *Drugs Aging* 2001;**18**:151-164.
30. Beckett N, Peters R, Fletcher A Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. *NEJM* 2008 **358**:1887-1898.
31. Casiglia E, Jordan J. Orthostatic hypotension: new views for an old problem, *J Hypertens* 2017; **35**: 947–949
32. Shaw B; Garland E, Black B, Paranjape SY, Shibao CA, Okamoto LE, Gamboa A, Diedrich A, Plummer WD, Dupont WD, Biaggioni I, Robertson D, Raj SR. Optimal diagnostic thresholds for diagnosis of orthostatic hypotension with a ‘sit-to-stand test’. *J Hypertens* 2017; **35**: 1019–1025
33. Grambsch PM and Therneau, TM. Proportional hazards tests and diagnostics based on weighted residuals. *Biometrika* 1994 **81**:515-526.
34. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poulter R, Ma S, Comsa M, Burch L, Fletcher A, Bulpitt C for the HYVET investigators. Incident dementia and BP lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial *Lancet Neurol* 2008; **7**: 683-689
35. Ricci F, Fedorowski A, Radio F, Romanello M, Tatasciore A, Di Nicola M, Zimarino M, De Caterina R. Cardiovascular morbidity and mortality related to orthostatic hypotension: a meta-analysis of prospective observational studies. *Eur Heart J* 2017; **36**: 1609-1617
36. Juraschek S. Daya N, Rawlings A, Appel L, Miller E, Windham B, Griswold M, Selvin E. Comparison of Earlier versus Later Orthostatic Hypotension Assessment Times in Middle-Age Adults of the Atherosclerosis Risk in Communities Study (ARIC) *Circulation* 2017;**135**:AP179
37. Moonen J, Foster-Dingley J, Ruijter W, Grond J, Craen A, Mast R. Effect of discontinuation of antihypertensive medication on orthostatic hypotension in older persons with mild cognitive impairment: the DANTE Study Leiden. *Age Ageing* 2016; **45**: 249-255
38. Shen W, Sheldon R, Benditt D, Cohen M, Forman D, Goldberger Z, Grubb B, Hamden M, Krahn A, Link M, Olshansky B, Raj S, Sandhu R, Sorajia D, Sun B, Yancy C. 2017

ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation*. 2017;136:e60-e122

Figure 1 Showing the Hazard Ratios and 95% Confidence Intervals for risk of cognitive decline and dementia for Orthostatic Hypotension (OH) and Subclinical Orthostatic Hypotension with symptoms (SOH) compared to neither.

Table 1 Characteristics of those with Orthostatic Hypotension (OH) compared to those without OH in the HYVET population

| Population characteristics mean (Standard Deviation) or n (%) | With OH N=538 | Without OH N=2583 | P= |
|--|----------------------|--------------------------|----------|
| Age | 83.9 (3.3) | 83.5 (3.1) | P=0.004 |
| Female | 61.5 (331) | 61.5 (1588) | P=0.984 |
| Sitting systolic BP | 174.5 (9.8) | 173.3 (9.2) | P<0.0001 |
| Sitting diastolic BP | 91.1 (8.7) | 90.9 (9.0) | P=0.688 |
| Standing systolic BP | 162.0 (10.9) | 169.3 (10.2) | P<0.0001 |
| Standing diastolic BP | 82.8 (9.1) | 89.9 (8.9) | P<0.0001 |
| Systolic orthostatic fall | 13.4 (7.5) | 4.0 (5.5) | P<0.0001 |
| Diastolic orthostatic fall | 8.3 (4.8) | 1.0 (4.3) | P<0.0001 |
| Diabetes | 46 (8.6) | 249 (9.6) | P=0.4666 |
| Mini Mental State Exam (MMSE) score | 24.9 (3.7) | 25.4 (3.8) | P=0.0003 |
| Incident dementia | 50 (9.3) | 191 (7.4) | P=0.133 |
| Incident cognitive decline (Protocol definition: MMSE fall) | 194 (36.1) | 712 (27.6) | P<0.0001 |
| Incident cardiovascular event (stroke, myocardial infarction, heart failure) | 37 (6.9) | 157 (6.1) | P=0.485 |
| Death | 31 (5.8) | 183 (7.1) | P=0.269 |
| Follow up in years (baseline to last available data) | 2.2 (1.5) | 2.4 (1.5) | P<0.0001 |
| Number randomised to trial treatment placebo arm | 268 (49.8) | 1273 (49.3) | P=0.8497 |

Table 2 Hazard ratios (HR) and associated 95% confidence intervals (CI) for the effect of Orthostatic Hypotension on risk of cognitive decline, dementia and cardiovascular events.

Stratified by age (80-84, ≥85 years), sex and education. Adjusted for baseline sitting systolic and diastolic BP, trial treatment and presence of diabetes.

| Outcome | Cognitive decline | | Dementia | | Cognitive decline and cardiovascular events** | | Dementia and cardiovascular events* | |
|------------------------------|---------------------------------|------------------|---------------------------------|------------------|---|------------------|-------------------------------------|------------------|
| Orthostatic Hypotension (OH) | Number of participants (events) | HR (95% CI) | Number of participants (events) | HR (95% CI) | Number of participants (events) | HR (95% CI) | Number of participants (events) | HR (95% CI) |
| No | 2,583 (712) | 1.00 | 2392 (191) | 1.00 | 1778 (805) | 1.00 | 2256 (327) | 1.00 |
| Yes | 538 (194) | 1.36 (1.15:1.59) | 488 (50) | 1.34 (0.98:1.84) | 322 (216) | 1.39 (1.19:1.62) | 457 (81) | 1.34 (1.05:1.72) |

* incident dementia, fatal and non-fatal cardiovascular events (heart failure, myocardial infarction, stroke) were defined as an event

**cognitive decline, fatal and non-fatal cardiovascular events (heart failure, myocardial infarction, stroke) were defined as an event.

Table 3 Hazard Ratios and 95% Confidence Intervals for effect of Subclinical orthostatic fall with recent symptoms and orthostatic hypotension on risk of adverse events (N=2100).

Stratified by age (80-84, ≥85 years), sex and education. Adjusted for baseline sitting systolic and diastolic BP, trial treatment and presence of diabetes.

| | Cognitive decline | | Dementia | | Cognitive decline and cardiovascular events ** | | Dementia and cardiovascular events * | |
|---------|-------------------|--|------------------|------------------|--|------------------|--------------------------------------|------------------|
| | Number of events | Hazard Ratio (95% Confidence Intervals (CI)) | Number of events | HR (95% CI) | Number of events | HR (95% CI) | Number of events | HR (95% CI) |
| Neither | 641 | 1.00 | 180 | 1.00 | 720 | 1.00 | 293 | 1.00 |
| SOH | | 1.56 (1.12:2.17) | | 1.79 (1.00:3.20) | | 1.51 (1.11:2.06) | | 1.79 (1.15:2.78) |
| OH | | 1.40 (1.15:1.69) | | 1.26 (0.87:1.84) | | 1.43 (1.20:1.72) | | 1.32 (0.98:1.78) |

* incident dementia, fatal and non-fatal cardiovascular events (heart failure, myocardial infarction, stroke) were defined as an event

**cognitive decline, fatal and non-fatal cardiovascular events (heart failure, myocardial infarction, stroke) were defined as an event.

Supplemental material

Supplementary text 1 Systematic review

Methods , search strategy and study selection

The databases MEDLINE and MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Embase Classic+Embase were searched using search terms including orthostatic hypotension, dementia, multi-infarct dementia, vascular dementia, alzheimer*, or cognit* adapted for optimised searching with Medline and Embase. (See supplement for details). Understanding of the relationship between BP and cognition has developed extensively over the last 20 years and search results were limited to those from 1997 to July 2017, further limitations included human rather than animal studies and articles in English (no resources were available for translation). Conference abstracts, editorials, comment, letters and review articles were excluded. The resulting abstracts were evaluated independently by two reviewers (RP and JP) and potentially eligible articles were selected for full text review. Any discrepancies were resolved by discussion between the two reviewers. All full text articles were extracted using a standardised data extraction table. Data from the included studies relating to population source, percentage of the sample that were female, length of follow-up, assessment of orthostatic hypotension, cognitive outcomes, analysis methods and results were extracted. In order to ensure the most robust assessment of incident dementia or cognitive decline data relating to samples that were pre-specified as cognitively intact at baseline were preferentially extracted.

For inclusion, articles were required to report on prospective longitudinal studies and on the relationship between orthostatic hypotension and incident cognitive decline (using cognitive measures collected at a minimum of two time points) or incident dementia. To ensure a broad assessment of the literature there were no minimum requirements for length of follow up, definition of OH or of cognitive decline or dementia. Study quality was examined per study using key questions based on the Critical Appraisal Skills Programme (8).

The systematic review is registered with the PROSPERO International prospective register of systematic reviews no. CRD42017075003

Results

Six hundred and twenty four abstracts were identified from database searching of Medline, 2805 from Embase and a further seven from reference searches. Abstract review resulted in 21 articles selected for full text evaluation of which seven were found to be eligible. Of the 14 that were excluded six were cross sectional (9-14), one was a case-control study (21), six lacked information on OH (15-20) one did not report results for incident cognitive decline (5). See supplemental figure 1, PRISMA flow chart. The seven eligible papers reported on longitudinal population studies from Sweden (22 23), (The Swedish Good Aging in Skåne Study (SGASS) and the Malmö Preventive Project), Italy (the Progetto Veneto Anziani study (PVA)), (24), the Netherlands (25), (the Rotterdam study), Singapore (Chinese adults) (6) (the Singapore longitudinal Aging Studies Cohort (SLASC)), the United States (USA) (the Atherosclerosis in the Community (ARIC) study) (26) and France (the 3-City study)(27).

The Malmö study population had a mean age of 45 (Standard Deviation (SD) 7)) years at baseline (23). The ARIC study included those aged between 45-64 at baseline and reported mean ages of 53.9 without OH and 57.3 with OH (26). The

Rotterdam and Singapore studies recruited those aged 55 and older at baseline and had mean ages of 68.5 (SD 8.6) (25) and 65.5 (SD 7.4) (6) years respectively. The Swedish SGASS study selected from nine age cohorts ranging from 60 to 93, mean age 68 (SD 8.5) at baseline (33). The Italian PVA study and the French 3-City study recruited those aged 65 and over. The PVA study also over sampled older adults. Baseline mean age in the PVA study was 71.4 (5.2) (24) and in the 3-City study 73.4 (SD4.9) (27). Follow up varied widely from one-two years (6), 4.4 years (24), six years (22), 7.5 years (27), ~6-9 years (26), 15.3 years (median) (25) and 28 years (SD 4) (23). The Swedish populations were 37% and 54% female respectively (22, 23), in the ARIC study 44.9% were female in those without OH and 45.8% in those with OH (26), in the Italian study females made up 59.4% (24), the Netherlands study 59.7% (25), the 3-City Study 60.5% (27) and in Singapore 65.8% (6).

OH was defined with slight differences in all five studies (supplemental table 2). All studies calculated orthostatic fall from a supine to standing position, however, the Skåne Study used a BP fall of >20mmHg systolic BP (BP) or >10mmHg diastolic BP after standing for 1-10 minutes or a fall of >40mmHg systolic or >20 diastolic immediately after standing (22). The other five studies used a fall of \geq 20mmHg systolic or \geq 10mmHg diastolic but within three minutes of standing (25), after three minutes of standing (7), after one minute of standing (23) after either one or three minutes of standing (24) immediately after standing (27) or with BP taken every two seconds for two minutes after standing (26). The 3-City study also calculated mild OH as a fall of >10mmHg systolic or >5 diastolic and severe OH as a fall of >30mmHg systolic or >15 diastolic immediately after standing (27). The prevalence of OH was 19% in the SGASS study (22), 18.6% in the Netherlands (25) 18.3% in Italy (24) 16.6% in Singapore (6), 13% in the 3-City study (27) 5.1% in the USA and 2.1% in the Malmö study (23). The Rotterdam study further reported a prevalence of OH at 30.6% in those aged 75 and over (25), the 3-City study reported 32% as having mild OH and 4.5% severe OH (27) and the Swedish SGASS study classified Orthostatic Intolerance (OI) as those with a BP (BP) fall less than that required for OH but with the presence of relevant symptoms e.g. unsteadiness (22).

Four studies used the Mini-Mental State Exam (MMSE) to assess cognitive function (6, 22, 24, 25). The ARIC study used a neuropsychological battery (26). The SGASS and 3-City studies used the Diagnostic Statistical Manual (DSM) IV and the Rotterdam study the DSMIIIR (22, 25, 27), for diagnosis of dementia, with additional standard criteria for dementia type (25, 27) and the Malmö study validated dementia diagnoses from a national registry using the DSMIIIR (23). See supplemental table 2.

Principal summary measures were OR and HR. All studies except the ARIC study reported data from populations that were specified as cognitively intact at baseline. The Malmö, SGASS, the Rotterdam and the 3-City studies reported that the presence of OH was likely to be associated with an increased risk of dementia (22, 23, 25, 27). For the SGASS this was a 93% increased risk OR 1.93 (1.19:3.14) (22); for the Rotterdam study, HR1.15 (1.00:1.34) (25). The Malmö study found a HR of 1.18 (0.73:1.89) for incident dementia, a HR of 1.02 (0.89:1.15) per 10mmHg fall in systolic BP and HR 1.22 (1.01:1.44) for diastolic BP (23). The 3-City study reported a 26% increased risk of dementia, HR1.26 (1.03:1.53) using a competing risk model taking illness and death into account and a HR of 1.19 (0.98:1.46) using a Cox proportional hazard regression model (27). The 3-City study also found statistically significant increases in risk of dementia when using the definitions of both mild and severe OH for both competing risk and Cox regression models, see supplemental table 2 for details (27). The SGASS further reported that OI may increase risk, particularly when subjective memory loss was taken into account (22). The ARIC study found no relationship between baseline OH and the quintile showing greatest cognitive decline for each cognitive test (26). Similarly the SLASC found no association between OH and risk of a fall in MMSE score (OR0.87 (0.61:1.23) (6). The PVA study reported similar results OR 0.78 (0.69:1.05) for cognitive

decline (a drop of ≥ 3 MMSE points over follow-up) and OR 1.01 (0.90:1.15) for cognitive impairment (MMSE ≤ 24) (24). There were no obvious relationships between length of follow up or study gender balance and outcome.

Overall study quality was adequate although full study details were often lacking, see supplemental table 3 for details. Studies used relatively standard but varying assessments of BP and cognitive outcomes and due to attrition all reported results for potentially selective populations (6, 22, 24, 25, 26, 27). In particular, the SLASC, the ARIC and two Swedish studies reported high attrition rates (6, 22, 23, 26) and for the SLASC study the follow up was too short to exclude reverse causality (6). There was insufficient information across the studies to allow meaningful comment on dementia type.

Conclusion

Overall, therefore, there is evidence to suggest that a diagnosis of OH may be associated with a subsequent increased risk of dementia and cognitive decline, however, there are no data available on the oldest old, that is those at highest risk of hypertension, OH and cognitive decline or dementia. Furthermore, few studies have investigated the relationship between the magnitude of the orthostatic fall and the degree of risk (i.e. the potential dose response), or the possible influence of 'sub-clinical' orthostatic fall and symptoms potentially associated with orthostatic fall. A greater understanding of relationships between orthostatic fall and cognitive outcome in older adults is essential to be able to identify those at risk of cognitive decline or dementia and to provide appropriate clinical support.

Supplementary text 2 search strategy

Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present>26 July 2017

Search Strategy:


-
- 1 hypotension.mp. or exp Hypotension, Orthostatic/ or exp Hypotension/
 - 2 exp Alzheimer Disease/ or alzheimer*.mp.
 - 3 exp Dementia/ or Dementia, Multi-Infarct/ or exp Frontotemporal Dementia/ or Dementia, Vascular/ or dementia.mp.
 - 4 exp Cognition Disorders/ or exp Cognition/ or cognit*.mp.
 - 5 2 or 3 or 4
 - 6 1 and 5
 - 7 limit 6 to (english language and humans and yr="1997 -Current")

Database: Embase Classic+Embase <1947 to 2017 July 26

Search Strategy:


-
- 1 orthostatic hypotension.af.
 - 2 (dementia or multi-infarct dementia or vascular dementia or alzheimer* or cognit*).af.
 - 3 1 and 2
 - 4 limit 3 to (human and english language and yr="1997 -Current")

Supplemental figure 1



Flow chart, systematic review.

Supplementary figure 2



Supplemental table 1 Characteristics of the longitudinal study populations reporting on orthostatic hypotension and cognitive outcomes in those without prior cognitive impairment

| Study | Population | Age (years) | Percent female | Follow up |
|---|--|--|--------------------------------|--|
| Swedish Good Aging in Skåne Study. Elmståhl et al 2014 | Longitudinal general population study. This sample excluded those with baseline Mini-Mental State Exam (MMSE) <24 or with a diagnosis of Mild cognitive Impairment (MCI) or dementia or prior stroke, myocardial infarction, angina pectoris and those unable to be tested for orthostatic hypotension. Baseline n=2931, 1832 were re-examined, 710 died or left the study, 23 had missing data. The final analytic sample was 1480 | 68 (Standard Deviation (SD) 8.5. From 9 age cohorts, aged 60,66, 72, 78, 81, 84, 87, 90, 93 | 54% | 6 years (assessments at baseline and 6 years) |
| Rotterdam Study. Wolters et al 2016 | Population based study recruited from an area of Rotterdam. This sample included those who attended centre baseline visit, were without dementia or stroke and where exam data was available for the assessment of OH. Baseline n=7983, 6626 were eligible or whom 6303 had appropriate OH data. | 68.5 (8.6) All aged >=55 at baseline. | 59.70% | Median 15.3 years (InterQuartile Range (IQR) 8.3:20.8). OH assessed in 1089-93, follow up until 2014. |
| Singapore Longitudinal Aging Studies Cohort Yap et al 2008 | Community living population of Chinese adults. Study included 2321 free of stroke or cardiovascular disease at baseline. 1485 attended the follow up visit (24 died, 785 were lost to follow up, 441 refused, 339 could not be contacted). | 65.5 (7.4) All aged >=55 years at baseline. | 65.8% (in the full sample) | One/two year follow up. Baseline was 2004/5 and follow up 2005/6 |
| Atherosclerosis Risk in Communities (ARIC) Study, Rose et al 2009 | 12,702 middle-aged African American and White men and women living in 4 communities: Maryland, Mississippi, Minnesota and North Carolina. At follow-up, 10,572, after exclusion of 1461 (no visit 4, death etc), 337 (no cognition test), and 332 (incident stroke). | No OH 53.9 (53.8-54.0), with OH (57.3 (56.8-57.7) | No OH 54.9 with OH 55.8 | Baseline (1987-89) plus 3 triennial visits (last one 1996-99). |

| | | | | |
|---|--|--|--------|---|
| | | | | |
| Malmö Preventive Project. Holm et al 2017. | <p>33,346 individuals living in Malmö.</p> <p>At follow up 18,204 were available. Missing data stated to range from 3 to 365 cases for different variables and these cases were not included in the respective analyses.</p> | 45 (7) | 37% | <p>time from baseline to follow-up visit 23 years (4),</p> <p>mean time from baseline to follow up for incident dementia 28 (4) years.</p> <p>Baseline 1974-1992, follow up 2002-2006. Mean</p> |
| Progetto Veneto Anziani Study. Curreri et al 2016 | <p>3099 community dwelling participants enrolled.</p> <p>1408 with data at follow up and without cognitive impairment (defined as an MMSE score ≤ 24)</p> | <p>71.4 (5.2)</p> <p>range 65-96</p> | 59.40% | <p>Mean follow-up 4.4 years.</p> <p>Baseline 1995-1997.</p> |
| Three-City Study. Cremer et al 2017 | <p>7425 recruited from the electoral roll in three French cities.</p> <p>Excluding those without prevalent dementia and with BP measures</p> | <p>73.4 (4.9)</p> <p>all aged 65 or over at baseline</p> | 60.50% | <p>Mean follow up 7.5 years</p> <p>Baseline 1999-2001, visits every 2/3 years.</p> |

Supplemental table 2 Results from longitudinal studies reporting on orthostatic hypotension and cognitive outcomes in those without prior cognitive impairment.

| Study | Assessment of OH | Cognitive outcomes | Analysis methods | Result |
|--|---|---|---|--|
| Swedish Good Aging in Skåne Study. Elmståhl et al 2014 | <p>Orthostatic hypotension was defined as a fall of >20mmHg SYSTOLIC BP or >10mmHg DIASTOLIC BP from supine pressure, after standing for 1-10 minutes or a fall of >40mmHg SYSTOLIC BP or >20 mmHg DIASTOLIC BP immediately after standing.</p> <p>Comprehensive examination by a physician including questions about symptoms such as unsteadiness, blackouts</p> <p>SGASS study also classified Orthostatic Intolerance (OI) as those with a BP (BP) fall less than that required for OH but with the presence of relevant symptoms e.g. unsteadiness (22).</p> <p>BP measured by a mercury sphygmomanometer.</p> | <p>Dementia</p> <p>Incident dementia diagnosed in accordance with the Diagnostic Statistical Manual (DSM)IV.</p> <p>Objective memory loss was defined as a follow up score of 0 or 1 on the 3 word recall sub-score of the MMSE in the absence of subjective memory loss.</p> <p>Subjective memory loss was also collected. MCI was defined as either subjective or objective memory loss at follow up.</p> | <p>Logistic regression comparing those who developed each outcome against those that developed none of the outcomes</p> | <p>19% had OH, 28% had past or present OI. 64% had hypertension Adjusted for age</p> <p>Controls vs objective memory loss OH OR 0.95 (0.68:1.33) OI OR 1.10 (0.83:1.47) Controls vs subjective memory loss OH OR 1.07 (0.68:1.69) OI OR 1.55 (1.06:2.27) Controls vs MCI OH OR1.23 (0.75:2.00) OI OR2.01 (1.33:3.05) Controls vs dementia OH OR1.93 (1.19:3.14) OI OR0.90 (0.55:1.50)</p> |
| Rotterdam Study. Wolters et al 2016 | <p>OH was based on change from supine to standing at 1, 2 and 3 minutes after standing and a fall of >=20mmHg SYSTOLIC BP or >=10mmHg DIASTOLIC BP within 3 minutes. Also categorised OH as >=20/10 but <30/15, >=30/15 but <40/20 and >=40/20</p> <p>BP was recorded by an automated machine, a Dinamap Critikan.</p> | <p>Dementia</p> <p>Screening at baseline and follow up used the Mini-Mental State Exam (MMSE) and Geriatric Mental State Schedule (GMS).</p> <p>An MMSE <26 or a GMS >0 triggered a more comprehensive exam with CAMDEX.</p> <p>Record linkage was also used to identify case of dementia.</p> | <p>Proportional hazards regression to examine the relationship between OH and later dementia or death.</p> | <p>18.6% with OH, 30.6% in those >=75 years</p> <p>Adjusted for age, sex, SYSTOLIC BP, DIASTOLIC BP, antihypertensive use, diabetes, ratio of total cholesterol to High Density Lipoprotein (HDL) cholesterol, lipid lowering medication, smoking status, alcohol intake, anticholinergic medication, Body Mass Index (BMI) and apoe genotype.</p> <p>For dementia HR 1.15 (1.00:1.34) For Alzheimers disease HR 1.17 (0.99:1.37) For vascular dementia HR 1.20 (0.73:1.96)</p> |

| | | | | |
|---|--|---|--|---|
| | | Diagnosis of dementia was made using the DSMIII-R and the NINCDS ADRDA for Alzheimer's Disease and NINDS AIREN for Vascular dementia. | | Also state that antihypertensive treatment had no effect. |
| Singapore Longitudinal Aging Studies Cohort Yap et al 2008 | OH was defined as a fall in SYSTOLIC BP of ≥ 20 mmHg or a fall of ≥ 10 mmHg in DIASTOLIC BP after 3 minutes standing from supine. BP measured by a mercury sphygmomanometer. | Cognitive change Assessment was using the MMSE. An MMSE < 24 was categorised as cognitive impairment, a fall of ≥ 1 point was categorised as cognitive decline. An additional analysis was carried out using ≥ 2 point fall to indicated cognitive decline. | Logistic regression was used to examine the relationship between baseline OH and cognitive decline. | 16.6% had OH. Adjusted for age, sex, education, vascular risk factors (dyslipidaemia, diabetes, smoking) anaemia, apoeE4, BMI, depression, BP level, use of BP altering medication, duration of self reported hypertension, baseline MMSE and length of follow up. For the whole sample the results for cognitive decline were OR0.87 (0.61:1.23) For those with hypertension OR0.84 (0.51:1.38) |
| Atherosclerosis Risk in Communities (ARIC) Study, Rose et al 2009 | Orthostatic fall calculated as difference between average standing and supine BP following 20 minutes supine rest, BP taken every 2 seconds for 2 minutes, followed by repeat procedure with subject standing. OH was defined as decrease in systolic BP (BP) by ≥ 20 mm Hg or diastolic BP by ≥ 10 mm Hg upon standing. BP measured with Dinamap 18465X oscillometric device | Cognitive change At visit 2 and 4, subjects completed a Delayed Word Recall Test (DWRT), a Digit Symbol Substitution Test (DSST) (subtest of Wechsler Adult Intelligence Scale -Revised, and The Controlled Oral Word Association Test (Word Fluency Test WFT) of the Multilingual Asphasic Examination. | Quintiles of change in cognitive performance between visit 2 and 4 calculated. Logistic regression analysis with lowest quintile compared with rest) to estimate association between OH and change in cognition, adjusted for various covariates. | 5.1% with OH. Association between baseline OH and cognitive decline over approx. 6 years (visit 2 to 4) Delayed word recall OR1.15 (0.94:1.42) Digit symbol substitution 1.13 (0.90:1.4); Word fluency 1.03 (0.82:1.28), each adjusted for age, race/centre, gender, education, Systolic BP, antihypertensive medication. Delayed word recall 1.08(0.86:1.35); Digit symbol substitution 1.05(0.83: 1.35); Word Fluency 1.03(0.80:1.31) each adjusted for covariates listed above plus current smoking and drinking, diabetes, carotid intima media thickness, low ankle brachial index, low density |

| | | | | |
|---|---|--|------------------------------------|---|
| | | | | lipoprotein cholesterol, resting heart rate, prevalent CHD, cancer, fair/poor self-reported health |
| Malmö Preventive Project. Holm et al 2017. | <p>OH defined as a fall of ≥ 20 mmHg systolic BP and or a fall of ≥ 10 mmHg diastolic BP after supine rest for 10 minutes and standing for one minute. Article specifies that all BP values were rounded up to nearest 5 mmHg and the mean value of two measures taken at each position was used.</p> <p>BP measured by a mercury sphygmomanometer.</p> | <p>Dementia</p> <p>Dementia diagnosis taken from the Swedish National Patient Register (SNPR) from baseline until Dec 2009.</p> <p>Dementia diagnoses were validated through review of medical records with physician input.</p> | Cox regression | <p>2.1% had OH.</p> <p>OH HR 1.18 (0.73:1.89)</p> <p>Per 10 mmHg fall; Systolic BP fall HR 1.02 (0.89:1.15) Diastolic BP fall HR 1.22 (1.01:1.44)</p> <p>Adjusted for age, gender, antihypertensive treatment, smoking, diabetes, prevalent cardiovascular disease, plasma cholesterol.</p> |
| Progetto Veneto Anziani Study. Curreri et al 2016 | <p>OH defined as a fall of ≥ 20 mmHg systolic BP and or a fall of ≥ 10 mmHg diastolic BP in BP measures taken after 1 or 3 minutes of standing and after supine rest for 5 minutes.</p> <p>BP measured by a mercury sphygmomanometer.</p> | <p>Cognitive change</p> <p>Mini Mental State Exam (MMSE)</p> <p>A drop in MMSE of ≥ 3 points classified as cognitive decline and a score of ≤ 24 as cognitive impairment</p> | States that Odds ratios were used. | <p>18.3% with OH.</p> <p>Cognitive decline OR 0.78 (0.69:1.05)</p> <p>adjusted for age and formal education using coefficients recommended for the Italian population</p> |

| | | | | |
|-------------------------------------|--|---|--|---|
| Three-City Study. Cremer et al 2017 | <p>OH defined as a fall of ≥ 20 mmHg systolic BP and or a fall of ≥ 10 mmHg diastolic BP in BP measures taken immediately after standing and after supine rest for 5 minutes. Analyses also carried out with mild OH defined as a fall of ≥ 10 mmHg systolic BP and or a fall of ≥ 5 mmHg diastolic BP and severe OH defined as a fall of ≥ 30 mmHg systolic BP and or a fall of ≥ 15 mmHg diastolic BP</p> <p>BP measured by an automatic oscillometric device (OMRON CP750).</p> | <p>Diagnosis of dementia using a three step procedure.</p> <p>Trained psychologists assessed cognitive function, at risk participants were seen by a neurologist at the Dijon site and all participants saw a neurologist at the Bordeaux and Montpellier sites. Final diagnosis made by an independent panel of experts based on DSMIV</p> | <p>Cox proportional Hazard Regression models with delayed entry. Date of dementia was defined as midpoint between the visit without a diagnosis and the date the diagnosis was made. Also used an illness death semiparametric multistate model designed to take into account the competitive risk of death.</p> | <p>13% with OH.</p> <p>For OH and dementia Cox model HR1.19 (0.98:1.46) Illness Death model HR 1.26 (1.03:1.53)</p> <p>For mild OH and dementia Cox model HR1.20 (1.04:1.40) Illness death model 1.23 (1.06:1.43)</p> <p>For severe OH and dementia Cox model HR1.54 (1.15:2.08) Illness death model HR1.51 (1.11:2.04)</p> <p>For OH and Alzheimer's Disease Cox model HR1.19 (0.91:1.57)</p> <p>For OH and vascular dementia Cox model HR1.42 (0.92:2.15)</p> |
|-------------------------------------|--|---|--|---|

Supplemental table 3 Study quality

| Study | Recruitment bias? | Exposure bias (assessments of risk factor exposure) | Outcome bias (assessment tool, blinded assessors?) | Follow up bias (attrition, length?) | Overview, risk of bias |
|---|--|--|---|---|------------------------|
| Swedish Good Aging in Skåne Study. Elmståhl et al 2014 | Moderate Longitudinal population study but selected population. | Low. Standard assessment of BP and OH | Low. Standard assessment of cognitive function administered by trained assessors | High. High attrition after baseline, some reasons given for attrition but no analyses to account for it. | Moderate |
| Rotterdam Study. Wolters et al 2016 | Moderate Longitudinal population study but selected population. | Low. Standard assessment of BP and OH. Used the American Autonomic Society and American Academy of Neurology Consensus Committee definition of OH. | Moderate. Standard assessment of cognitive function using a multistage process. Medical record based diagnosis are likely to be more open to bias than face to face assessment. | Low. State that assessment was 94% complete by the end of data collection. Imputed missing data in covariate and state that rerunning the analyses omitting the first 5 years or follow up to try to exclude reverse causality did not materially change the results. | Low-Moderate |
| Singapore Longitudinal Aging Studies Cohort Yap et al 2008 | Moderate. Selected population | Low. Standard measurement of BP and definition of OH | Moderate. Standard assessment for cognitive function but limited to a screening instrument. Fall of 1 point to indicate impairment was not well justified. | High. High attrition after baseline, some reasons given for attrition but no analyses to account for it. Missing data was excluded. | Moderate |
| Atherosclerosis Risk in Communities (ARIC) Study, Rose et al 2009 | Moderate. Participants sampled from 4 areas, but ethnic density varied between the 4 communities, so possible bias in overall sample | Low. Standard measurement of BP and definition of OH | Low. Standard tests for assessment of cognitive function | High. 17% lost for follow-up, some reasons given, mainly non-attendance at 4th visit. | Moderate |
| Malmö Preventive Project. Holm et al 2017. | Moderate. Not clear whether population was representative. | Moderate. Standard criteria for OH but not clear whether rounding of BP values took place before or after calculation of OH. | High. Standard criteria used by research team to validate dementia diagnoses, however, diagnoses taken from medical registries may underestimate incidence and may be more subject to changing diagnostic patterns over time than | High.. No details of reasons for attrition or adjustment. States that prevalence of OH lower, 2.1% in those with follow up compared to 6.1% in the full baseline sample. | Moderate-high |

| | | | | | |
|---|--|--------------------------------|---|--|--------------|
| | | | use of standard research protocols with direct participant assessment. | | |
| Progetto Veneto Anziani Study. Cureri et al 2016 | Moderate, population was sampled to ensure male to female ratio of 2:3 and older adults were over sampled. | Low. Standard criteria for OH. | Moderate . Standard assessment for cognitive function but limited to a screening instrument | Moderate, however, details are provided regarding attrition or exclusion from analytical sample. | Moderate |
| Three-City Study. Cremer et al 2017 | Moderate, although sampled from the electoral role. | Low. Standard criteria for OH. | Low, standard criteria for diagnosis and regular visits. | Moderate, however, details are provided regarding exclusion from analytical sample. Those in the study sample were younger and have fewer cardiovascular risk factors than those excluded. | Low-Moderate |

Supplemental table 4 Characteristics of those with Subclinical orthostatic fall with recent symptoms and Orthostatic Hypotension in the subset with symptom data.

| Population characteristics mean (Standard Deviation) or n (%) | Neither N=1623 | Orthostatic Subclinical orthostatic fall with recent symptoms N=105 | Orthostatic hypotension N=381 | P-values ^a |
|--|-----------------------|--|---|------------------------|
| Age | 83.45 (3.12) | 83.13 (2.72) | 83.83 (3.26) | 0.05 ^b |
| Female | 60.4 (980) | 74.3 (78) | 63.8 (243) | 0.01 ^g |
| Sitting systolic BP – baseline | 173.4 (9.8) | 174.7 (10.0) | 175.2 (10.0) | <0.01 ^c |
| Sitting diastolic BP- baseline | 89.7 (9.6) | 91.9 (9.3) | 90.5 (8.9) | 0.07 ^b |
| Standing systolic BP- baseline | 169.7 (11.1) | 168.4 (11.3) | 161.5 (11.4) | <0.0001 ^d |
| Standing diastolic BP- baseline | 89.3 (9.5) | 89.6 (9.3) | 82.2 (9.3) | <0.0001 ^d |
| Systolic orthostatic fall- baseline | 3.7 (6.2) | 6.3 (5.3) | 13.7 (8.0) | <0.0001 ^{e,f} |
| Diastolic orthostatic fall- baseline | 0.5 (4.8) | 2.3 (4.6) | 8.3 (5.2) | <0.0001 ^f |
| Mini Mental State Exam (MMSE) score baseline | 25.2 (3.9) | 25.1 (3.4) | 24.5 (3.8) | <0.01 ^c |
| Incident dementia | 132 (8.1) | 13 (12.4) | 35 (9.2) | 0.28 |
| Incident cognitive decline (Protocol definition: MMSE fall) | 462 (28.5) | 40 (38.1) | 139 (36.5) | <0.01 ^h |
| Incident cardiovascular event (stroke, myocardial infarction, heart failure) | 97 (6.0) | 13 (12.4) | 26 (6.8) | 0.03 ^g |
| Death | 596 (5.9) | 18 (17.1) | 22 (5.8) | P<0.0001 ⁱ |
| Follow up (baseline to last available data) | 2.4 (1.5) | 2.3 (1.3) | 2.1 (1.5) | P<0.001 |
| Participants reporting light-headedness and or unsteadiness and or faintness as having bothered them ‘a lot’ or ‘extremely’ during the preceding week. | 7 (0.43) | 105 (100) | 4 (1.1) | N/A |

^a global p-values from one-way analysis of variance;

^b There were no significant pairwise differences between the groups (Tukey-Kramer test, 5% level)

^c There was a significant pairwise difference between the “Neither” and “Orthostatic hypotension” groups (Tukey-Kramer test, 5% level)

^d There was a significant pairwise difference between the “Neither” and “Orthostatic hypotension” groups and between the “Orthostatic Subclinical orthostatic fall with recent symptoms” and “Orthostatic hypotension” groups (Tukey-Kramer test, 5% level)

^e global p-value from W test (similar to F-test for one-way analysis of variance but more robust when there are unequal variances).

^f All the pairwise comparisons between the groups were significant (Tukey-Kramer test, 5%)

^g Examination of the adjusted Chi-squared residuals suggests there are no unusually high or low counts in any of the cells.

^h Examination of the adjusted Chi-squared residuals suggests a difference is between the “Neither” and “Orthostatic Subclinical orthostatic fall with recent symptoms”/“Orthostatic hypotension” groups.

ⁱExamination of the adjusted Chi-squared residuals suggests a difference is between the “Neither” and “Orthostatic hypotension” groups and the “Orthostatic Subclinical orthostatic fall with recent symptoms” group.

Supplemental table 5 Results of proportional hazard regression analyses for systolic and diastolic OH separately. Stratified by age (80-84, >=85 years), sex and education. Adjusted for baseline sitting systolic and diastolic BP, trial treatment and presence of diabetes.

| | Cognitive decline | Dementia | Cognitive decline and cardiovascular events | Dementia and cardiovascular events |
|--------------|--|------------------|---|------------------------------------|
| | Hazard Ratio (95% Confidence Intervals (CI)) | HR (95% CI) | HR (95% CI) | HR (95% CI) |
| Systolic OH | 1.17 (0.91:1.50) | 0.86 (0.50:1.49) | 1.22 (0.97:1.54) | 1.11 (0.75:1.62) |
| Diastolic OH | 1.47 (1.23:1.75) | 1.69 (1.22:2.34) | 1.49 (1.26:1.75) | 1.54 (1.18:2.00) |

Supplemental table 6 Results of proportional regression analyses using a more severe definition Orthostatic Hypotension*. Stratified by age (80-84, ≥ 85 years), sex and education. Adjusted for baseline sitting systolic and diastolic BP, trial treatment and presence of diabetes.

| | Cognitive decline | | Dementia | | Cognitive decline and cardiovascular events | | Dementia and cardiovascular events | |
|------------------------------|-------------------|--|------------------|------------------|---|------------------|------------------------------------|------------------|
| | Number of events | Hazard Ratio (95% Confidence Intervals (CI)) | Number of events | HR (95% CI) | Number of events | HR (95% CI) | Number of events | HR (95% CI) |
| Orthostatic Hypotension (OH) | 906 | 1.49 (1.16:1.90) | 241 | 1.40 (0.90:2.27) | 1021 | 1.51 (1.19:1.90) | 498 | 1.35 (0.92:1.98) |

*Defined as a fall of >20 mmHg systolic BP ad or a fall of >10 mmHg diastolic BP.

Supplementary analyses 1

Summary meta-analysis

| Study | * Ratio | SE | Approximate 95% CI | | |
|-------|---------|----------|--------------------|------|-----------|
| 1 | 1.93 | 0.247522 | 1.19 | 3.14 | SGASS |
| 2 | 1.34 | 0.160709 | 0.98 | 1.84 | HYVET |
| 3 | 1.19 | 0.101696 | 0.98 | 1.46 | 3 Cities |
| 4 | 1.18 | 0.24268 | 0.73 | 1.89 | Malmö |
| 5 | 1.15 | 0.074662 | 1 | 1.34 | Rotterdam |

| Stratum | Standardized Effect | Standard Error | % Weights (fixed, random) | | |
|---------|---------------------|----------------|---------------------------|-----------|-----------|
| 1 | 1.93 | 0.247522 | 4.688799 | 5.652385 | SGASS |
| 2 | 1.34 | 0.160709 | 11.122669 | 12.8318 | HYVET |
| 3 | 1.19 | 0.101696 | 27.777073 | 28.835204 | 3 Cities |
| 4 | 1.18 | 0.24268 | 4.877786 | 5.872458 | Malmö |
| 5 | 1.15 | 0.074662 | 51.533673 | 46.808153 | Rotterdam |

Fixed effects (inverse variance)

Pooled * ratio = 1.211428 (95% CI = 1.090624 to 1.345612)

Z (test test * Ratio differs from 1) = 3.578511 P = 0.0003

Non-combinability of studies

Cochran Q = 4.462408 (df = 4) P = 0.347

Moment-based estimate of between studies variance = 0.002075

I² (inconsistency) = 10.4% (95% CI = 0% to 67.7%)

Random effects (DerSimonian-Laird)


Pooled * ratio = 1.221427 (95% CI = 1.086264 to 1.373409)



Z (test * Ratio) = 3.342813 P = 0.0008

Bias indicators

Begg-Mazumdar: Kendall's tau = 0.8 P = 0.0833 (low power)

Egger: bias = 1.632025 (95% CI = -1.031496 to 4.295546) P = 0.1463





Appendix 1

Abbreviations

| | |
|--|-------|
| Blood Pressure | BP |
| Diagnostic Statistical Manual | DSM |
| Hazard Ratio | HR |
| Hypertension in the Very Elderly Trial | HYVET |
| Mini-Mental State Exam | MMSE |
| Orthostatic Hypotension | OH |
| Subclinical Orthostatic Hypotension | SOH |